Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 19/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740051 | 0.91 | NR1I3 (0.43) | NR1I3NR1I2DPP4CYP1A2CYP3A4 | |
| SCHEMBL14739888 | 0.88 | NR1I3 (0.40) | NR1I3NR1I2DPP4 | |
| SCHEMBL14740103 | 0.88 | NR1I3 (0.41) | NR1I3NR1I2DPP4 | |
| SCHEMBL14739332 | 0.88 | MAPK13 (0.41) | NR1I3NR1I2DPP4 | |
| SCHEMBL14739351 | 0.87 | MAPK1 (0.44) | NR1I3NR1I2CYP1A2 | |
| SCHEMBL14739596 | 0.87 | MAPT (0.39) | NR1I3NR1I2DPP4 | |
| SCHEMBL14739599 | 0.87 | NR1I3 (0.41) | NR1I3NR1I2DPP4 | |
| SCHEMBL14739276 | 0.86 | NR1I3 (0.43) | NR1I3NR1I2DPP4 | |
| SCHEMBL14739390 | 0.85 | NR1I3 (0.45) | NR1I3DPP4 | |
| SCHEMBL14739626 | 0.85 | NR1I3 (0.41) | NR1I3NR1I2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | claimed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | claimed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR3 | NR1I3 197/4885NR1I2 147/4885DPP4 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.